Kimelman & Baird LLC Takes $58,000 Position in Guardant Health, Inc. (NASDAQ:GH)

Kimelman & Baird LLC bought a new stake in Guardant Health, Inc. (NASDAQ:GH) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 1,900 shares of the company’s stock, valued at approximately $58,000.

Other hedge funds also recently added to or reduced their stakes in the company. R Squared Ltd bought a new stake in Guardant Health in the fourth quarter valued at $26,000. SBI Securities Co. Ltd. acquired a new position in Guardant Health during the fourth quarter worth about $43,000. Jones Financial Companies Lllp grew its holdings in Guardant Health by 43.5% during the fourth quarter. Jones Financial Companies Lllp now owns 2,696 shares of the company’s stock worth $82,000 after acquiring an additional 817 shares during the period. Van ECK Associates Corp grew its holdings in Guardant Health by 47.4% during the fourth quarter. Van ECK Associates Corp now owns 2,887 shares of the company’s stock worth $88,000 after acquiring an additional 929 shares during the period. Finally, KBC Group NV grew its holdings in Guardant Health by 63.6% during the fourth quarter. KBC Group NV now owns 5,658 shares of the company’s stock worth $173,000 after acquiring an additional 2,200 shares during the period. 92.60% of the stock is currently owned by institutional investors.

Guardant Health Price Performance

Shares of Guardant Health stock opened at $42.89 on Monday. The firm has a market cap of $5.29 billion, a price-to-earnings ratio of -12.05 and a beta of 1.50. Guardant Health, Inc. has a 52-week low of $15.81 and a 52-week high of $50.89. The stock has a 50-day simple moving average of $43.01 and a 200-day simple moving average of $32.94.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings results on Thursday, February 20th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.15). The firm had revenue of $201.81 million for the quarter, compared to analyst estimates of $192.50 million. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. As a group, equities research analysts predict that Guardant Health, Inc. will post -2.9 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts recently issued reports on GH shares. Stifel Nicolaus lifted their target price on Guardant Health from $45.00 to $53.00 and gave the stock a “buy” rating in a report on Friday, February 21st. Morgan Stanley lifted their price target on Guardant Health from $42.00 to $52.00 and gave the stock an “overweight” rating in a research note on Thursday, March 6th. The Goldman Sachs Group lifted their price target on Guardant Health from $49.00 to $56.00 and gave the stock a “buy” rating in a research note on Friday, February 21st. Piper Sandler lifted their price target on Guardant Health from $34.00 to $50.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 26th. Finally, Barclays started coverage on Guardant Health in a research note on Thursday, January 23rd. They issued an “overweight” rating and a $60.00 price target on the stock. Twenty investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $48.40.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.